From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
Arizona has a sizable and rapidly growing bioscience industry. State bioscience firms employed 25,686 in 2016 in 1,310 individual business establishments. Industry employment has grown by 9 percent since 2014, twice the growth rate of the nation, with four of the five major subsectors adding jobs during the period. Both drugs and pharmaceuticals and research, testing and medical labs have experienced double-digit job growth since 2014. Arizona inventors have been awarded nearly 2,000 bioscience-related patents since 2014, among the second quintile of states in patent activity. Since 2015, NIH awards to Arizona institutions have increased, reaching $189 million in FY 2017. (Get The Facts)
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
Brain State Technologies announced the release of its BST Optimization Suite 4.0 software platform on Friday September 21, 2012. The system is based on 10 years of research and development, and employs over 3,000,000 brainwave patterns. More than 200 global offices feed the world’s largest relational data warehouse of brainwave activity 24/7/365. This continuous data […]
Provista Diagnostics Announces the Closing of Additional $2.5 Million Series A Preferred Financing
By Alexis Blue, University Communications | September 20, 2012 Researchers think the drug 3K3A-APC, currently undergoing clinical trials in Europe, may help reduce brain damage and improve motor skills after a stroke.
According to a receint article in FierceMedicalDevices, Medtronic ($MDT) believes its pump technology could pair well with the next generation of Alzheimer’s treatments, and the company is on the hunt for pharmaceutical partners.
- AZBio PEERS - Intellectual Property
- Open Door at ASU Biodesign Tempe
- AdvaMed Fly In 2020
- 02/25/2020 - 02/26/2020
- 2020 Health Policy Symposium - Improving Healthcare Through Transparency and Collaboration
- 2020 McKenna Lecture by Susan Dentzer